This role independently leads the end-to-end forecasting process for Cell Therapy assets within the Multiple Myeloma disease area using AI-first methodologies.
Base: $152,150 - $184,370; Bonus/Equity: Additional incentive cash and stock opportunities available; Benefits: Health coverage, 401(k), paid time off, and wellbeing support programs
Must-have
Nice-to-have
Not specified